Dongyan Cao

ORCID: 0000-0002-7260-2495
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • MicroRNA in disease regulation
  • Testicular diseases and treatments
  • Sarcoma Diagnosis and Treatment
  • PARP inhibition in cancer therapy
  • Urologic and reproductive health conditions
  • CRISPR and Genetic Engineering
  • Neuroblastoma Research and Treatments
  • Reproductive Biology and Fertility
  • Circular RNAs in diseases
  • Cancer Genomics and Diagnostics
  • Extracellular vesicles in disease
  • Cancer-related molecular mechanisms research
  • Urinary and Genital Oncology Studies
  • nanoparticles nucleation surface interactions
  • DNA Repair Mechanisms
  • Urological Disorders and Treatments
  • Cancer Immunotherapy and Biomarkers
  • Cytomegalovirus and herpesvirus research
  • Pediatric Urology and Nephrology Studies
  • Glioma Diagnosis and Treatment
  • Genetic factors in colorectal cancer
  • Reconstructive Facial Surgery Techniques
  • Cancer Research and Treatments
  • Immunotherapy and Immune Responses

Chinese Academy of Medical Sciences & Peking Union Medical College
2012-2025

Peking Union Medical College Hospital
2012-2025

National Clinical Research Center for Digestive Diseases
2024

Erasmus MC Cancer Institute
2021

Rotterdam University of Applied Sciences
2021

Konkuk University
2021

// Huimin Bai 1, 2, * , Haixia Li Weihua 1 Ting Gui Jiaxin Yang Dongyan Cao Keng Shen Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy Sciences & College, Beijing China 2 Chao-Yang Capital University, These authors have contributed equally to this work Correspondence to: Cao, e-mail: caodongyan@pumch.cn Shen, shenkeng@vip.sina.com skpumch@126.com Keywords: ovarian cancer, intratumoral heterogeneity, cell subclones, invasion migration, RNA-Seq...

10.18632/oncotarget.4550 article EN Oncotarget 2015-07-14

Cellular exosomes are involved in many disease processes and have the potential to be used for diagnosis treatment. In this study, we compared characteristics of derived from human ovarian epithelial cells (HOSEPiC) three cancer cell lines (OVCAR3, IGROV1, ES-2) investigate differences between originating normal malignant cells. Two established colloid-chemical methodologies, electron microscopy (EM) dynamic light scattering (DLS), a relatively new method, nanoparticle tracking analysis...

10.1007/s13277-015-4105-8 article EN Tumor Biology 2015-10-22

Circular RNAs (circRNAs) are regarded as a novel class of widespread endogenous non-coding RNAs, which may play important roles in tumorigenesis by regulating gene expression. Nevertheless, the characterization circRNAs epithelial ovarian cancer (EOC) remains largely unknown. This study aimed to investigate circRNA expression profiles EOC. A total 54 EOC specimens and normal tissues (controls) were collected. circRNA-sequencing based identified 4 compared with tissues. data validated reverse...

10.3892/ijo.2018.4566 article EN International Journal of Oncology 2018-09-20

Ovarian clear cell carcinoma (OCCC) is resistant to chemotherapy, with limited treatment options for advanced and recurrent disease. The prevalence of OCCC differs by region. Assessing the expression programmed death ligand 1 (PD-L1), PD-1, CD8+T infiltration in crucial, as their correlation patient survival may provide valuable prognostic insights. We collected data from 36 samples 18 patients, including pairs tumors adjacent nonneoplastic samples. optimized multiplex immunofluorescence...

10.1038/s41598-025-89270-z article EN cc-by-nc-nd Scientific Reports 2025-02-08

Objective The current treatment for early-stage neuroendocrine carcinoma of the cervix (NECC) mainly relies on operation and chemotherapy. We want to evaluate values postoperative radiation in NECC.

10.1080/07853890.2025.2466667 article EN cc-by-nc Annals of Medicine 2025-03-18

Introduction: Ovarian cancer is a highly malignant with poor prognosis. At present, there no accurate strategy for predicting the prognosis of ovarian cancer. A prediction signature associated DNA repair genes in was explored this study. Methods: Gene expression profiles were downloaded from GEO, UCSC, and TCGA databases. Cluster analysis, univariate stepwise regression used to identify as potential targets prognostic survival prediction. The top evaluated by immunohistochemical staining...

10.3389/fgene.2019.00839 article EN cc-by Frontiers in Genetics 2019-09-12

To define genetic profiling of homologous recombination (HR) deficiency in Chinese ovarian cancer patients.we have applied next-generation sequencing to detect deleterious mutations through all exons 31 core HR genes. Paired whole blood and frozen tumor samples from 50 women diagnosed with epithelial carcinomas were tested identify both germline somatic variants.Deleterious HR-mutations identified 36% the patients. Another 5 patients had only mutations. BRCA2 was most frequently mutated....

10.3802/jgo.2017.28.e39 article EN cc-by-nc Journal of Gynecologic Oncology 2017-01-01

B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) might be an appropriate biomarker in the management of epithelial ovarian cancer (EOC). However, biological role BMI1 and its relevant molecular mechanism needs further elaboration. Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is excellent genome-editing tool scarcely used EOC studies. We first applied CRISPR/Cas9 technique to silence cells; thereafter we accomplished various vivo vitro...

10.1186/s13048-018-0406-z article EN cc-by Journal of Ovarian Research 2018-04-23

Objective Non-platinum chemotherapy is used in platinum resistant/refractory ovarian cancer patients but offers limited efficacy, especially those who develop resistance after ≤2 lines of based chemotherapy. This phase II study aimed to evaluate the efficacy and safety oral niraparib plus etoposide cancer. Methods Platinum chemotherapy, histologically confirmed as non-mucinous epithelial cancer, regardless biomarker status, were eligible. Patients received with a starting dose 200 mg/100 mg...

10.1136/ijgc-2024-005386 article EN International Journal of Gynecological Cancer 2024-07-29

Objective: To explore the appropriate treatment of malignant germ cell tumor (MGCT) in female genital system, and to analyze factors influencing both therapeutic response survival outcome.Methods: A cohort 230-Chinese women diagnosed with MGCT system was retrospectively reviewed prospectively followed.The demographic pathological features, extent disease surgery, efficiency, recurrence were analyzed.Results: MGCTs from different origins shared a similar strategy response, except that all...

10.3802/jgo.2016.27.e26 article EN cc-by-nc Journal of Gynecologic Oncology 2016-01-01

The use of flaps in vulvar cancer-related reconstruction has been increasing, but few studies have evaluated the outcome and quality life patients after this surgery. purpose study was to evaluate outcomes using musculocutaneous/skin with advanced recurrent malignancies. Patients malignancies who underwent different types were retrospectively reviewed. Patient a focus on prognosis. Thirty-six enrolled, 58.33 % them used anterolateral thigh flap (ALT), 16.67 pudendal (PTF), 11.11 deep...

10.1186/s12885-015-1792-x article EN cc-by BMC Cancer 2015-11-05

The aim of this study was to evaluate the conservative management and prognosis primary vaginal endodermal sinus tumor rhabdomyosarcoma in children. Medical records children with between 1996 2015 were reviewed. A total 24 patients (median age, 12 months; range, 7-44 months) included study, comprising 17 7 rhabdomyosarcoma. Among tumor, 15 initially treated at our hospital chemotherapy alone, 2 other hospitals surgery chemotherapy. All botryoid received without well-defined protocols. At a...

10.18632/oncotarget.18829 article EN Oncotarget 2017-06-28

Ovarian cancer has the worst prognosis of any gynecological malignancy, and generally presents with metastasis at advanced stages. Copy number variation (CNV) frequently contributes to alteration oncogenic drivers. In this study, we sought identify genetic targets in heterogeneous clones from human ovarian cancers cells. We used array-based technology systematically assess all genes CNVs cell models clonally expanded A2780 SKOV3 lines distinct highly minimally invasive/migratory capacities....

10.18632/oncotarget.14767 article EN Oncotarget 2017-01-20

<h3>Introduction/Background</h3> Niraparib is the first PARP inhibitor to be approved for first-line maintenance (1LM) treatment of all patients with newly diagnosed advanced ovarian cancer. The RENI-1 study (NCT04986371) was designed evaluate patterns, efficacy and safety in cancer who received niraparib as 1LM therapy real world. <h3>Methodology</h3> prospectively enrolled eligible therapy. primary endpoint including initiation time maintenance, starting dose regimens. Secondary endpoints...

10.1136/ijgc-2024-esgo.619 article EN 2024-03-01

Epithelial ovarian cancer (EOC) is a lethal form of gynecological malignancy. Some EOC patients experience relapse after standard primary debulking surgery (PDS) and adjuvant chemotherapy (ACT). Identifying molecular residual disease (MRD) by circulating tumor DNA (ctDNA) detection can timely signal the potential for relapse. However, research on usage ctDNA MRD in limited. Fifty-one who received PDS ACT were included. Targeted sequencing based panel 1021 cancer-related genes, along with...

10.1186/s12885-024-13222-5 article EN cc-by-nc-nd BMC Cancer 2024-12-22

Malignant mixed ovarian germ cell tumors are very rare, accounting for ~5.3% of all malignant (MOGCTs), with a high degree malignancy. The treatment patients persistent, refractory, or platinum-resistant MOGCT is not well defined. objective this case report was to analyze the importance chemotherapy, salvage surgery and target therapy in patient refractory OGCT after first-line chemotherapy failure. We reported 34 year-old woman suffered from advanced cytoreductive surgery, series...

10.2147/ott.s176854 article EN cc-by-nc OncoTargets and Therapy 2018-10-01

Objective: To assess the outcomes of retreatment using progestin in patients with recurrent endometrial cancer (EC) after achieving complete response (CR) fertility sparing hormonal treatment.Methods: We reviewed retrospectively who had recurrence CR by treatment presumed stage IA, grade 1, endometrioid EC.All were given medroxyprogesterone acetate or megestrol concurrent LNG-IUD.The primary end point was rate.The secondary points pregnancy outcome, pathologic disease progression, and 2nd...

10.3802/jgo.2021.32.s1.oo1 article EN 2021-01-01
Coming Soon ...